Introduction
Peroxisome proliferator-activated receptor-g (PPARg) is a member of the PPAR family of ligand-activated nuclear receptors, which were initially demonstrated to have important roles in lipid metabolism (see Berger and Moller (2002) for a review). The three PPAR isoforms, a, g, and d (also designated b) bind as heterodimers with the retinoic acid X receptor (RXR). These heterodimers, complexed with either coactivators or corepressors, recognize specific peroxisome-proliferator response elements (PPAR-RE) in the promoter regions of their target genes. A critical role for PPARg was first established in adipocyte differentiation, where activation leads to induction of adipocyte-specific proteins (Tontonoz et al., 1994) . PPARg activation has also been implicated as a regulator of processes associated with atherosclerosis. Targeted deletion of PPARg has shown that it plays a critical role in the regulation of cholesterol homeostasis by controlling the expression of genes that mediate cholesterol efflux from cells (Akiyama et al., 2002) . This is likely mediated through induction of the cholesterol transporter known as ABCA1. Activation of PPARg has also been shown to inhibit the growth and migration of vascular smooth muscle cells, which may ameliorate the formation of atherosclerotic lesions (Marx et al., 1998) .
PPARg is activated by polyunsaturated fatty acids and eicosanoids. In particular, 15-deoxy-D 12,14 -PGJ 2 (dPGJ 2 ), a derivative of arachidonic acid, has been shown to activate PPARg with micromolar affinity . Lipoxygenase products of linoleic acid, 9-and 13-HODE, also have micromolar affinities for PPARg (Nagy et al., 1998) . It is not clear, however, whether any of these molecules represent actual physiologic regulators of PPARg, and a recent study has found that endogenous levels of dPGJ 2 do not change during adipocyte differentiation (Bell-Parikh et al., 2003) . Synthetic activators of PPARg include the thiazolidindiones (TZDs), such as ciglitazone and troglitazone . These compounds have insulin-sensitizing and antidiabetic activity, which is likely mediated at least in part through PPARg activation. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit eicosanoid production by blocking cyclooxygenase activity, also activate PPARg, albeit at higher concentrations than required for cyclooxygenase inhibition (Lehmann et al., 1997) .
The role of PPARg in the development and progression of cancer has been the subject of extensive study during the past several years. This has been spurred by the development of synthetic agents that specifically bind to the PPARg isoform and are capable of inducing PPARg activity, resulting in altered expression of PPARg-target genes. The efficacy of these compounds as anticancer agents has been examined in a variety of cancers including colon, breast, prostate, and lung (reviewed in Grommes et al., 2004) . Consistent with a role in adipocyte differentiation, PPARg activators (troglitazone) inhibited growth and led to induction of solid tumor differentiation in three patients with intermediate-to high-grade liposarcoma (Demetri et al., 1999) . TZDs have also been shown to inhibit the growth of breast cancer and prostate cancer cells (Mueller et al., 2000) . Inactivating mutations in the PPARg gene have also been identified in colon cancers (Kinzler and Vogelstein, 1996; Sarraf et al., 1999) , suggesting that PPARg may act as a tumor suppressor gene, and mice with one copy of the PPARg gene( þ /À) have an increased tendency to develop colon tumors compared to wild-type littermates when exposed to azoxymethane. A large number of studies have examined the role of PPARg in colon cancer, but have yielded apparently conflicting data. Pharmacological activators of PPARg inhibit the growth of colon cancer cell lines in vitro, and in xenograft models . However, administration of PPARg activators to APC Min mice, which have an inactivating mutation in the adenomatous polyposis Coli (APC) gene resulted in an increase in tumor number (Lefebvre et al., 1998; Saez et al., 1998) . This apparent conflicting role may be a result of alterations in the normal differentiation of colonic epithelial cells, which occurs in the APC Min mouse. Activators of PPARg also inhibit the growth of breast cancer cells . However, a recent study has indicated that loss of one copy of the PPARg gene does not increase propensity for breast tumors (Cui et al., 2002) , making the role of PPARg in breast cancer less well-defined.
Interpreting many of these experiments is complicated by findings that PPARg activators can engage additional pathways that may impact on growth and apoptosis of cancer cells. Specifically, TZDs can inhibit activation of NF-kB, which participates in cell survival in a PPARindependent fashion (Rossi et al., 2000; Straus et al., 2000) . Recent studies have also shown that these agents can suppress production of inflammatory cytokines (Jiang et al., 1998) as well as inhibiting COX-2 expression (Subbaramaiah et al., 2001) , which may affect proliferation or apoptosis in these cells. Chawla et al. (2001) have in fact demonstrated that proliferation of PPARg-null embryonic stem cells is inhibited by TZDs.
The role of PPARg in the development of lung cancer has not been studied as extensively as in colon or breast cancer. Several studies have demonstrated that activation of PPARg can inhibit growth of lung cancer cells (Chang and Szabo, 2000; Tsubouchi et al., 2000) . In samples from human lung tumors, decreased expression of PPARg was correlated with poor prognosis (Sasaki et al., 2002) . In a separate study, expression of PPARg was examined by immunohistochemistry. Well-differentiated adenocarcinomas had greater frequency of PPARg-positive cells than poorly differentiated samples. Since all of the studies to date have examined the effects of pharmacological agents, we have undertaken a molecular approach to define more precisely the biological role of PPARg in non-small-cell lung cancer (NSCLC). While our earlier study indicated that PPARg activation may influence both NSCLC and small-cell lung cancer (SCLC), we have focused on NSCLC in this study employing several well-characterized NSCLC cell lines. Our data indicate that the role of PPARg in these cells is mediated through modulating the state of differentiation of these cells with consequences on invasion and metastasis.
Results

PPARg overexpression prevents colony formation in soft agar but not NSCLC proliferation
Since anchorage-independent growth is frequently used as an index of transformed cell growth and tumorigenicity, we sought to determine if stable overexpression of PPARg could inhibit transformed growth of lung cancer cells by assessing the ability of two independent NSCLC cell lines, H2122 and H157, to form colonies in soft agar. Cells were stably transfected with wild-type PPARg using retroviral-mediated gene transfer, and multiple stable clones selected by immunoblotting for PPARg protein (Wick et al., 2002) . Expression of functional PPARg was confirmed by transiently transfecting stable clones with a construct encoding three copies of a consensus PPAR-RE driving a luciferase reporter (Wick et al., 2002) . Promoter activity was increased in all clones from two to fivefold compared to cells stably transfected with empty vector (LNCX). In both cell lines, overexpression of PPARg resulted in a marked impairment in colony formation compared to cells stably transfected with empty vector (LNCX) (Figure 1a) . Furthermore, the extent of inhibition was correlated with the level of PPARg protein overexpression, and PPAR-RE promoter activity (Wick et al., 2002) . In several clones, the level of PPAR-RE activity was comparable to that observed in untransfected cells stimulated with pharmacological activators (Wick et al., 2002) . These cells (H157-PPARg-19, and H2122-PPARg-16) showed a partial inhibition of colony formation ( Figure 1a) . However, to clearly define the specific pathways mediated by PPARg, clones showing the highest level of PPARg expression (H157-PPARg-12 and H2122-PPARg-18) and their respective controls (H157-LNCX and H2122-LNCX) were used in all subsequent studies.
Previous studies have reported that exposure of NSCLC to synthetic PPARg activators blocks tumor progression by inhibiting the proliferation of NSCLC and/or inducing apoptosis (Chang and Szabo, 2000; Tsubouchi et al., 2000; Keshamouni et al., 2004) . We therefore asked if stable overexpression of PPARg had similar growth inhibitory effects under standard tissue culture conditions. Although H157-PPARg and H2122-PPARg showed dramatically reduced soft agar colony formation, both cell lines demonstrated no alterations in cell growth compared to control cells as measured by cell titer proliferation assays (Figure 1b) . To confirm these findings, we directly examined DNA synthesis rates and apoptosis in H2122 cells. Overexpression of PPARg had no effect on BrdU incorporation in response to serum stimulation (Figure 1c ). In addition, very few apoptotic nuclei were detected in either H2122-LNCX or H2122-PPARg cells, as assayed by cleaved caspase-3 immunodetection, or by examination for condensed apoptotic nuclei (data not shown). Consistent with our in situ observations, we found that fulllength caspase-3, and activated, cleaved caspase-3 protein expression levels remained unchanged in lysates from H2122-PPARg cells as compared to control 3-D culture of normal epithelial cells within a reconstituted basement matrix has been shown to recapitulate several aspects of cell proliferation, tissue architecture, and differentiation in vivo (Debnath et al., 2003) . Additionally, a number of studies have used 3-D tissue culture systems to reveal differences in cells expressing oncogenic Ras, which are not apparent when these cells are grown under standard 2-D tissue culture conditions (Janda et al., 2002a, b) . We therefore examined the behavior of H2122-LNCX and H2122-PPARg cells under 3-D tissue culture conditions. To better compare the characteristics of NSCLC with nontransformed epithelial cells grown in 3-D culture, the behavior of a normal lung rat epithelial cell line, RL-65 (Roberts et al., 1990) , was used as a control. Consistent with previous studies of normal breast epithelial cells (Debnath et al., 2003) , RL-65 plated at single cell density, underwent approximately 6-8 days of proliferation, followed by polarized organization of the outer cells (cells in contact with matrix) to form a single-cell thick spheroid structure. Cells in the center of the spheroid structure underwent programmed cell death in order to generate a lumen. Figure 2a and b show representative confocal images of sections along the z-axis, and a 3-D reconstruction of the z-stack of RL65 cells cultured for 8 days and immunofluorescently stained with anti phospho-Ezrin/Radixin/Moesin (P-ERM) and DAPI. P-ERM staining was detected in actin-rich structures, with enrichment on apical surfaces consistent with polarized structure of breast epithelial cells in 3-D culture (Debnath et al., 2002) . We next compared H2122-PPARg with H2122-LNCX cells.
After 8 Figure 2a) . Additionally, we used antibodies to E-cadherin, as a marker of cell-cell junctions and active caspase 3, to detect apoptotic cells, in these 3-D cultures (Figure 2g , h, and i). The spheroid structures formed by RL65 cells had nearly complete hollowing out of the lumen and cells undergoing apoptosis (red stain) were localized to the periphery of the structure (as most luminal cells had already undergone apoptosis) (Figure 2g ). Importantly, spheroid structures formed by H2122-PPARg cells were beginning to hollow out the lumen and some apoptotic cells were detected in the center of the structure, consistent with PPARg expression promoting a differentiated phenotype to these H2122 cells (Figure 2i ). In sharp contrast, the cell aggregates formed by H2122-LNCX control cells showed no evidence of polarization, with evenly distributed apoptotic cells ( Figure 2h ). Ecadherin expression was markedly increases in H2122 cells expressing PPARg as compared to H2122 control cells. Importantly, this E-cadherin expression was localized to the cell-cell junctions of the spheroid structure formed by H2122-PPARg cells, resembling the expression pattern observed in the spheroid structures formed by normal epithelial cells.
Protein expression is altered when H2122-PPARg cells are grown in 3-D cell culture
To quantitate changes in protein expression, extracts were prepared from H2122-LNCX and H2122-PPARg cells grown in standard, 2-D tissue culture, as well as in 3-D tissue culture. Consistent with results obtained with immunofluorescence, E-cadherin expression was markedly increased in H2122-PPARg cells compared to H2122-LNCX when grown in 3-D culture (Figure 3) . This difference was blunted in cells grown in 2-D culture, suggesting that manifestation of the enhanced differentiation, mediated by PPARg, is increased in the 3-D model. Conversely, expression of ezrin and phospho-ezrin was dramatically decreased in H2122-PPARg grown in 3-D compared to LNCX controls, while expression in the two cell lines was not signficantly different in 2-D culture. Increased ezrin expression has been reported to be linked with highly metastatic cells Yu et al., 2004) . Surprisingly, levels of phospho-Erk1/Erk2 were dramatically reduced in H2122-PPARg cells grown in 3-D culture (and to a lesser extent, in cells grown in 2-D). This finding is in sharp contrast to previous reports, which have reported an induction of phospo-Erk1/Erk2 in NSCLC stimulated with PPARg agonists (Keshamouni et al., 2004 ). Our studies demonstrate not only that PPARg agonists may engage signaling pathways not specific to PPARg but also that 3-D cell culture reveals significant alterations in protein expression that are not evident when cells are grown in standard 2-D cell culture.
PPARg overexpression inhibits tumor progression in vivo
To assess the effects of PPARg overexpression on NSCLC growth in vivo, xenograft models were employed with cells being implanted into two different sites. In the first of these, equal numbers of H2122-LNCX or H2122-PPARg cells were inoculated into the left lung lobe of athymic nude rats (see Materials and methods and Chan et al., 2002; Whitehead et al., 2003) . Animals were killed after 20 days and whole lungs were examined. Extensive tumor formation and metastasis were detected in the mediastinum and contra-lateral lungs of animals inoculated with H2122-LNCX cells. Lungs removed from animals injected with H2122-PPARg cells formed primary tumors at the site of inoculation (arrow in Figure 4a ), but showed no obvious signs of metastasis and maintained normal lung architecture (Figure 4a) . A separate group of animals (n ¼ 12 in each group) was monitored for survival over a 60-day period. As shown in Figure 4b , animals inoculated with H2122-PPARg had a marked survival advantage, with 2/3 of the animals living past 30 days, while all animals inoculated with control H2122-LNCX cells died by day 22 postprocedure. In total, 50% of the H2122-PPARg inoculated animals were still alive at 60 days postprocedure (data not shown). The KaplanMeier survival curves were found to be significantly different (P ¼ 0.039). The ratio of lung weight to body weight has been used to quantitate tumor burden (Malkinson, 1979; March et al., 2001) . These values were determined at 10 and 20 days after inoculation.
As an additional control, noninoculated rats were used to assess the variability in this assay. We found that relative lung weights showed minimal variability on H2122-LNCX and H2122-PPARg cells were imaged using a phase contrast microscope (c and d, respectively) and using confocal imaging following immnunofluorescent staining with antibodies directed to laminin V (green) and phospho-Ezrin/Radixin/Moesin (red) (e and f, respectively). RL65, H2122-LNCX, and H2122-PPARg cells were immnunofluorescently stained with antibodies directed to cleaved-caspase-3 and E-cadherin (g, h, and i, respectively) either day 10 or 20 ( Figure 5a ). Consistent with our survival study, relative lung weights (i.e. tumor burdens) in animals inoculated with H2122-PPARg and H2122-LNCX were not significantly different at day 10, but by day 20 postprocedure, animals inoculated with H2122-LNCX showed a statistically significant increase as compared to rats inoculated with H2122-PPARg cells ( Figure 5a ). As a second xenograft model, H2122-LNCX or H2122-PPARg was injected into the flank of nude rats (six animals per group). In this model, tumors grow but generally do not metastasize (Wick et al., 2002) . Tumor size was quantitated over a 41-day period using digital calipers. In contrast to the results of the orthotopic lung xenograft, no difference in the size of the tumors formed by H2122-LNCX or H2122-PPAR cells was observed at any of the time points (Figure 5b ). At the final time point, the rats were killed and the tumors were weighed on an analytical balance. No difference in tumor burden was detected (Figure 5c ). These in vivo observations support our hypothesis that PPARg inhibits tumorogenesis by mechanisms related to invasion and metastasis rather than cell proliferation.
PPARg specifically impairs NSCLC invasion
Since overexpression of PPARg selectively affected metastasis in the lung, we directly compared migration and invasion in H2122-PPARg cells with H2122-LNCX. Migration was measured using a Transwell assay, in which equal numbers of cells in serum-free media were plated onto wells containing 5% serum in the bottom chamber. Cells migrating through the Transwell were stained with DAPI and counted using the Metamorph software package. As shown in Figure 6a , no significant difference was observed in the migration of the two cell populations. We have confirmed this finding using a 'scratch' assay (where the rate of filling-in of a gap made by scratching a monolayer of cells is monitored), and found no differences between the two cell lines (data not shown). Invasiveness was determined using Transwells coated with Matrigel. Under these conditions, H2122-PPARg cells showed a marked impairment in invasiveness compared to H2122-LNCX cells (Figure 6b ). This difference was observed at all time points examined.
Discussion
Although the role of PPARg in the development of lung cancer has not been studied as extensively as in colon or breast cancer, several studies have demonstrated that pharmacological activators of PPARg can inhibit growth of NSCLC cells (Chang and Szabo, 2000; Tsubouchi et al., 2000; Wick et al., 2002) . In samples from human lung tumors, decreased expression of PPARg was correlated with poor prognosis (Sasaki et al., 2002) . In a separate study, expression of PPARg was examined by immunohistochemistry: well-differentiated adenocarcinomas possessed more PPARg-positive cells than poorly differentiated samples (Theocharis et al., 2002) . More recently, pharmacological agonists of PPARg have been reported to inhibit tumor progression using xenografts with an NSCLC cell line (Keshamouni et al., 2004) . Owing to the PPARg-independent effects of presently available pharmacological agonist, our laboratory has undertaken a molecular approach using overexpression of wild-type PPARg in lung cancer cells (Wick et al., 2002) . In the present study, we show that Figure 5 While PPARg over expression reduces tumor mass when adenocarcinoma cells are grafted into the lung, cell growth is unaltered in the subcutaneous environment. Equal numbers of H2122-LNCX or H2122-PPARg cells were inoculated orthotopically into the lungs of nude rats as in Figure 1 . Equal numbers of cells were also injected subcutaneously in the flank of nude rats. Orthotopically injected rats were killed at days 10 and 20 postprocedure, lungs were then removed and weighed, and normalized to the body weight of the respective animal to determine the relative lung tumor burden mass. *Po0.05 vs Control; **Po0.05 vs H2122-LNCX (a). Subcutaneous tumors were monitored over a 41-day period using digital calipers to determine tumor volume over time (b). On day 41, the animals were killed and surgically removed tumors were weighed (c) Figure 6 PPARg specifically inhibits adenocarcinoma-cell invasion but not migration. Migration of H2122 cells was assayed in Transwell chambers. Cells were plated in 0.2% FBS and 5% FBS placed in the bottom chamber. Cells on the bottom chamber were stained with DAPI and counted using the Metamorph software. No difference was seen in cell migrating at either 72 or 96 h (a). Invasion was measured using Transwells coated with Matrigel. Cells were plated as above and counted at 96 h. H2122-PPARg cells had a markedly slower invasive rate (b) Our data demonstrate that increased expression of PPARg selectively inhibited anchorage-independent growth of multiple NSCLC lines. However, in contrast to exposure of NSCLC to TZDs, increased expression of PPARg did not affect cell proliferation or apoptosis under standard 2-D tissue culture conditions. This suggests that the induction of growth arrest or apoptosis caused by TZDs is likely mediated, at least in part, through engagement of other effecter pathways. The lack of an effect on growth was confirmed by our xenograft experiments. When tumor cells were inoculated into the flank of nude rats, the rate of tumor growth was unaffected by overexpression of PPARg. In general, these subcutaneous tumors become vascularized, but will not metastasize, and are an in vivo correlate for growth of the primary tumor. In contrast, when cells were inoculated into the lungs of nude rats, there was a dramatic inhibition of tumor number and metastasis from cells overexpressing PPARg, and this correlated with improved survival of the animals. We would therefore propose that in the environment of the lung, where tumor cells can migrate and invade new sites to form metastases, PPARg activation inhibits this process.
Direct measurement of migration and invasion revealed that overexpression of PPARg selectively inhibits invasion. Migration and invasion of cells is mediated through regulated activity of the Rho family of low molecular weight G-proteins, specifically RhoA, Rac, and Cdc42 (Takai et al., 2001) , and also involves regulation of proteases required to digest the extracellular matrix. From preliminary examination of microarray data, a number of genes related to migration and angiogenesis are altered in cells overexpressing PPARg (data not shown). Specifically, DLC-1, which has homology to RhoGAP, is induced in cells overexpressing PPARg. This gene has been proposed to be a tumor suppressor gene in NSCLC, and overexpression inhibits transformed growth (Yuan et al., 2004) .
3-D tissue culture systems have been shown to provide an environment that more accurately reflects the in vivo environment. Elegant studies have demonstrated that normal breast epithelial cells form polar acini when grown under these conditions (Debnath et al., 2002) . Our data indicate that RL-65 cells, which represent an untransformed lung epithelial cell line, form similar structures. This could be contrasted with H2122 cells, which form nonpolar aggregates when grown in 3-D Matrigel cultures. Importantly, overexpression of PPARg caused re-establishment of polarity in H2122 cells, an adenocarcinoma cell line. This was associated with induction of E-cadherin expression, and localization to tight junctions. Increased expression of PPARg was not sufficient to cause the cells to form hollow spheroid structures; however, our data indicate that cleaved caspase 3 activity is increased in the middle of the cell aggregate, whereas in control H2122 cells, caspase 3 activity was randomly distributed throughout the aggregates. Based on these data we propose that activation of PPARg, in this case through overexpression of the protein, drives the cells to acquire a more epithelial-like phenotype. We would also propose that the establishment of this more differentiated phenotype is responsible, at least in part, for the decreased invasiveness, and suggest that PPARg facilitates a mesenchymal to epithelial transition in these cells. Earlier studies have shown that exposure of lung cancer cells to the TZD ciglitazone can also upregulate markers associated with a more differentiated state (Chang and Szabo, 2000) . In this study, apoptosis was also induced by ciglitazone. Based on findings presented in this study, we propose that the induction of differentiation markers is mediated through PPARg, whereas the apoptotic response was mediated through non-PPAR pathways. Interestingly, we observed that overexpression of PPARg resulted in decreased levels of phospho-ERK. This is opposite to the effect of troglitazone, which induced phospho-ERK in NSCLC (Keshamouni et al., 2004) . Phosphorylation of PPARg by ERKs has been demonstrated to be inhibitory to PPARg -mediated transcriptional activity (Adams et al., 1997) . Thus, TZD stimulation of NSCLC, while activating PPARg activity, also stimulates a pathway that inhibits PPARg, limiting the extent of PPARg activitation. The development of more selective PPARg agonists, which do not engage other signaling pathways, may result in a much stronger response than observed with the current class of agents.
Lung cancer is the leading cause of cancer death for both men and women in the US. In fact, more deaths will occur this year due to lung cancer than breast, prostate, and colorectal cancers combined (Kerr, 2001) , underscoring the need for new therapeutic approaches. Recent findings indicate that a subset of patients respond to inhibitors of the EGF-receptor, and that this is associated with specific somatic mutations in the receptor (Lynch et al., 2004; Paez et al., 2004) . PPARg activators represent a new class of agents that may have efficacy in the treatment of lung cancer. Our data and those of others raise the hope that PPARg activators may be effective in inhibiting the metastasis of these cells, which is closely linked to survival. As with EGFreceptor inhibitors, these agents may be targeted to specific subpopulations of lung cancer cells. Preliminary trials using TZDs have provided disappointing results in treating both breast (Burstein et al., 2003) and colon cancer (Kulke et al., 2002) . However, our data would suggest that more specific pharmacological activators of PPARg may have utility as specific inhibitors of metastasis.
Materials and methods
Cell culture
NSCLC lines (H2122 and H157) were obtained from the University of Colorado Health Science Center Tissue Culture Core. Cells were maintained in RPMI containing 10% fetal bovine serum. H2122-LNCX, H2122-PPARg, H157-LNCX, and H157-PPARg stable clones have been previously described (Wick et al., 2002) .
3-D cell culture
Cells were grown in 3-D basement membrane cultures according to Debnath et al. (2003) with the following modifications: growth factor reduced Matrigel (BD Bioscience) was combined in a 1 : 1 ratio with full-serum media (RPMI þ 10% FCS). In total, 80 ml was added to each well of an eight-well glass slide chamber (LAB-TEK, Nalge Nunc International) and allowed to solidify for 2 h in a 371C incubator. Cells were trypsinized, counted and diluted to 25 000 cells/ml. A 20% Matrigel solution was prepared in fullserum media. The cell suspension was combined in a 1 : 1 ration with the 20% Matrigel solution and 200 ml of this mixture was added to each well for a final concentration of 5000 cells/well in 10% Matrigel. Cells were fed with 4% matrigel (in full-serum media) every other day for a term of 8-10 days of culture.
Xenograft studies
In the orthotopic lung model system, female athymic nude rats (6 weeks old) obtained from the National Cancer Institute were maintained in pathogen-limited conditions at the Animal Resource Center, University of Colorado Health Sciences Center. At 1 day before tumor cell implantation, rats were treated with 400 cGY total body irradiation (Co 60 ) to increase immunosuppression and tumor take. Equal numbers (5 Â 10 6 in 100 ml of serum-free medium) of human adenocarcinoma H2122 cells overexpressing PPARg (H2122-PPARg) or stably transfected with empty vector (H2122-LNCX) were instilled intratracheally into the left lung of anesthetized rats Whitehead et al., 2003) using a 3-in 22-guage catheter (Popper & Sons, Inc., new Hyde Park, NY, USA). Rats (24 instilled with H2122-LNCX, 12 of which were killed at day 10, and 12 of which were killed at day 20; and 24 instilled with H2122-PPARg, 12 of which were killed at day 10, and 12 of which were killed at day 20) were monitored daily for survival or killed at days 10 and 20 postprocedure for tumor burden quantification. To determine lung tumor burden, the rats were weighed prior to killing and their respective lung weights were normalized to body weights.
For the subcutaneous rat tumor model, nude rats were treated as above except that cells (2.5 Â 10 6 ) were injected into the flank of the animal (six in each group). Tumor volume was quantitated over time using digital calipers. On the final day of measurement, rats were killed, and tumors were surgically removed and weighed on an analytical balance. Digital photos of isolated lungs were taken using an Olympus 2500 L digital camera (Tokyo, Japan).
The Kaplan-Meier survival curves were analysed using SigmaStat 3.1 (Systat Software Inc., Richmond, CA, USA). Fisher's exact test was applied to examine the differences in tumor growth between H2122-LNCX and H2122-PPARg cells. A value of Po0.05 was considered significant.
Indirect immunofluorescence
Cells grown in 3-D culture were immunostained as previously described with some modifications (Debnath et al., 2003) Briefly, cells were fixed with 2% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min at room temperature, permeabilized with 0.5% Triton X-100, and rinsed three times with 100 mM glycine. The cells were then incubated in primary block (7.7 mM NaN 3 , 0.1% bovine serum albumin, 0.2% Triton X-100, 0.05% Tween-20, and 10% goat serum in PBS) for 1 h at room temperature. Following a 30 min incubation in secondary block (primary block plus 20 mg/ml goat anti-mouse F(ab 0 ) 2 fragment (Jackson Immuno Research)), cells were incubated with primary antibodies, lamininV (at 1 : 100, Chemicon International), phospho-ERM (at 1 : 100, Cell Signaling Technology), cleaved caspase-3 (at 1 : 50, Cell Signaling Technology), and E-cadherin (at 1 : 100, BD Biosciences) overnight at room temperature. Cells were rinsed three times prior to incubation with secondary antibodies (Alexa Fluor 488 goat anti-mouse, Alexa Fluor 568 goat anti mouse, Alexa Fluor 488 goat anti-rabbit, and Alexa Fluor 568 goat anti-rabbit, all used at 1 : 250, Molecular Probes). Cells were mounted using Vectashield fluorescent mount media containing 4 0 ,6-diamidino-2-phenylindole (Vector Laboratories). Structures grown in 3-D matrices were imaged and acquired on a Zeiss 510 Meta NLO confocal microscope (Carl Zeiss Microimaging, Thornwood, NY, USA). Images were analysed using Zeiss Image Examiner software. At least 20 aggregate structures were examined in each of three independent experiments.
BrdU incorporation assays
Cells were grown on treated coverslips (Microscope Cover Glass, Fisherbrand) and incubated with 10 mM BrdU for the last 1-h of incubation. Cells were then washed with Hanks buffer and fixed in 4% PFA in PBS. Cell were permeabilized with 0.5% Triton X-100 for 5 min at room temperature, washed with PBS, and acid treated with 2 N HCl, for 1 h at room temperature. After extensive washing, the cells were blocked in 5% goat serum, 0.2% Triton X-100 in PBS for 1 h at room temperature. Anti-BrdU primary antibody (at 1 : 40, Abcam, Inc.) was diluted in blocking solution and added to the cells for 1 h at room temperature. Following three washes, the cells were incubated in secondary antibody (Alexa Fluor 568-conjugated goat anti-rat (1 : 500, Molecular Probes)) for 1 h at room temperature. Coverslips were mounted onto slides using Vectashield fluorescent mount media containing 4 0 ,6-diamidino-2-phenylindole (Vector Laboratories). BrdU-positive nuclei were scored using an inverted fluorescent miscroscope (Nikon) and reported as a percentage of the total nuclei per optical field.
Immunoblot analysis
Cells grown in 2-D culture were lysed in cold RIPA buffer (10 mM TrisHCl, 150 mM NaCl, 1% NaDOC, 1% Triton X-100, 0.1% SDS) containing protease inhibitors, centrifuged at 10 000 g for 5 min, and the supernatant was saved. Cells grown in 3-D matrigel were first isolated using BD Cell Recovery Solution (BD Biosciences) as per the manufacture's instructions. These cells were then processed as the cells grown in 2-D culture. Protein was quantitated using Bio-Rad Protein Assay reagent (Bio-Rad). Protein samples were run on precast 4-20% Gradient Tris-HCl gels (Bio Rad).
Migration and invasion assays
For measurements of cell migration, cells were plated on the top of Transwells (BD Biosciences) containing 8 mm pores, in media containing 0.1%. FCS, and allowed to migrate in response to 5% FCS. At the indicated times, cells on the top of the Transwell were removed by scraping with a Q-tip and cells on the bottom were fixed with 4% paraformaldehyde. Nuclei on the bottom of the Transwell were stained with DAPI and quantitated in a fluorescent microscope using the Metamorph Software. Four independent fields were counted for each Transwell. For measurements of cell invasion, identical numbers of cells were plated on Matrigel-coated Transwell inserts. At the indicated time, cells on the top were removed with a Q-tip and cells on the bottom of the Transwell fixed and counted as described above.
Soft agar colony formation
For determination of anchorage-independent growth, singlecell suspensions containing 10 000 cells in 1.5 ml RPMI 1640 containing 10% fetal bovine serum and 0.3% nobel agar were layered over a base prepared in 35 mm diameter dishes of RPMI 1640, 10% fetal bovine serum, and 0.5% agarose. The dishes were incubated for 3-4 weeks at 371C in a humidified CO 2 incubator. Live colonies were stained for 5-20 h at 371C with nitroblue tetrazolium chloride (NBT; 1 mg/ml), visualized under a microscope and counted.
Abbreviations PPAR, peroxisome proliferator-activated receptor; NSCLC, non-small-cell lung cancer; TZD, thiazolidindione; PPAR-RE, PPAR response element; NSAIDs, nonsteroidal anti-inflammatory drugs; P-ERM, phospho-Ezrin/Radixin/Moesin.
